Q-omics provides the consensus-scored CATSPERB profile across patient tissues and cancer cell-line models. CATSPERB expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CATSPERB is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, CATSPERB protein abundance shows 20,585 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, THCA, and LSCC as cancer lineages where CATSPERB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CATSPERB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CATSPERB survival associations across molecular data types. CATSPERB RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CATSPERB RNA expression–survival associations across cancer types. High CATSPERB expression shows unfavorable associations in LGG, SCLC and OV, but favorable associations in MESO, HNSC and COAD. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CATSPERB RNA expression.
This table summarizes CATSPERB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CATSPERB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CATSPERB shows lower tumor expression in THCA and KICH and higher tumor expression in STAD, BLCA, LUAD and BRCA. The THCA box plot shows higher CATSPERB RNA expression in normal versus tumor tissue (log2 FC = −0.259, t-test p < 0.001).
This table shows molecular features associated with CATSPERB in patient tissues and cancer cell lines. In patient samples, CATSPERB shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CATSPERB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
